Indaptus Financial Statements From 2010 to 2024

INDP Stock  USD 2.25  0.03  1.35%   
Indaptus Therapeutics financial statements provide useful quarterly and yearly information to potential Indaptus Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Indaptus Therapeutics financial statements helps investors assess Indaptus Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Indaptus Therapeutics' valuation are summarized below:
Market Capitalization
19 M
Earnings Share
(1.77)
There are currently one hundred twenty fundamental trends for Indaptus Therapeutics that can be evaluated and compared over time across competitors. Investors and active traders are advised to confirm Indaptus Therapeutics' regular fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 07/12/2024, Enterprise Value is likely to grow to about 1.7 M, while Market Cap is likely to drop slightly above 11.4 M.
Check Indaptus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Indaptus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 K, Interest Expense of 710.1 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.29. Indaptus financial statements analysis is a perfect complement when working with Indaptus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Indaptus Therapeutics Correlation against competitors.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Indaptus Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.5 M14.9 M21.4 M
Very volatile
Short and Long Term Debt Total310 K175.1 K955.6 K
Slightly volatile
Other Current Liabilities1.9 M1.9 M3.5 M
Slightly volatile
Total Current Liabilities3.4 M2.8 M6.6 M
Slightly volatile
Property Plant And Equipment Net165.2 K173.9 K2.6 M
Slightly volatile
Accounts Payable1.4 M806 K2.8 M
Slightly volatile
Cash16.1 M13.4 M11.5 M
Slightly volatile
Non Current Assets Total1.5 M928.7 K5.3 M
Slightly volatile
Non Currrent Assets Other843.3 K754.7 K2.6 M
Slightly volatile
Cash And Short Term Investments19.9 M13.4 M13.4 M
Slightly volatile
Net Receivables18 K19 K2.3 M
Slightly volatile
Common Stock Shares Outstanding4.8 M8.4 MM
Slightly volatile
Liabilities And Stockholders Equity23.5 M14.9 M21.4 M
Very volatile
Non Current Liabilities Total69.7 K73.3 K1.1 M
Slightly volatile
Other Current Assets653.4 K633.2 K359.8 K
Slightly volatile
Other Stockholder Equity59.5 M57.4 M149.3 M
Slightly volatile
Total Liabilities3.6 M2.8 M7.6 M
Slightly volatile
Total Current Assets21.4 M14 M16.1 M
Slightly volatile
Short Term Debt147.1 K101.7 K397.5 K
Slightly volatile
Common Stock71.8 K75.6 K506.9 K
Slightly volatile
Property Plant Equipment70.9 K93.5 K29.5 K
Slightly volatile
Property Plant And Equipment Gross118.1 K173.9 K37.4 K
Slightly volatile
Capital Stock76.6 K96.6 K43 K
Slightly volatile

Indaptus Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 K1.3 K569.8 K
Slightly volatile
Interest Expense710.1 K676.3 K143.8 K
Slightly volatile
Selling General Administrative5.3 M8.7 M2.3 M
Slightly volatile
Selling And Marketing Expenses1.1 K1.2 KM
Slightly volatile
Other Operating Expenses12.4 M16.4 M27 M
Slightly volatile
Research Development7.3 M7.6 M19.5 M
Slightly volatile
Cost Of Revenue1.2 K1.3 K569.8 K
Slightly volatile
Total Operating Expenses12.3 M16.4 M26.4 M
Slightly volatile
Net Interest Income710.1 K676.3 K143.9 K
Slightly volatile
Interest Income710.1 K676.3 K143.9 K
Slightly volatile
Reconciled Depreciation1.5 K1.3 KK
Slightly volatile

Indaptus Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings777.2 K1.3 M540.3 K
Slightly volatile
Stock Based Compensation1.7 MM700.7 K
Slightly volatile
Begin Period Cash Flow15 M9.6 M30.8 M
Slightly volatile
Depreciation1.2 K1.3 K569.8 K
Slightly volatile
Total Cash From Financing Activities396.6 K417.5 KM
Pretty Stable
End Period Cash Flow16.1 M13.4 M11.5 M
Slightly volatile
Other Cashflows From Investing Activities305.5 K155.3 K403.5 K
Slightly volatile
Change To Netincome3.4 M3.2 M824.8 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital0.01910.01450.0345
Slightly volatile
Average Payables1.8 M1.6 M1.8 M
Slightly volatile
Payables Turnover0.00150.00160.163
Slightly volatile
Cash Per Share1.511.590517.1705
Slightly volatile
Capex To Operating Cash Flow0.01660.01520.0242
Slightly volatile
Days Payables Outstanding202.6 K229.1 K98.8 K
Slightly volatile
Income Quality0.770.86920.7364
Slightly volatile
Net Debt To EBITDA1.150.80520.6949
Slightly volatile
Current Ratio3.885.04512.8646
Slightly volatile
Graham Number7.327.7058179
Slightly volatile
Debt To Equity0.01910.01450.0345
Slightly volatile
Interest Debt Per Share0.01980.02080.8963
Slightly volatile
Debt To Assets0.01220.01170.0194
Slightly volatile
Days Of Payables Outstanding202.6 K229.1 K98.8 K
Slightly volatile
Ebt Per Ebit1.160.94171.2329
Slightly volatile
Long Term Debt To Capitalization0.00320.00540.0026
Slightly volatile
Total Debt To Capitalization0.01850.01430.0331
Slightly volatile
Debt Equity Ratio0.01910.01450.0345
Slightly volatile
Quick Ratio3.754.81682.7882
Slightly volatile
Dividend Paid And Capex Coverage Ratio64.868.21426
Slightly volatile
Net Income Per E B T1.091.11.0186
Slightly volatile
Cash Ratio2.894.81682.0641
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.171.0414
Slightly volatile
Capital Expenditure Coverage Ratio64.868.21426
Slightly volatile
Debt Ratio0.01220.01170.0194
Slightly volatile

Indaptus Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.4 M14.8 MM
Slightly volatile

Indaptus Fundamental Market Drivers

Cash And Short Term Investments13.4 M

Indaptus Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Indaptus Therapeutics Financial Statements

Indaptus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Indaptus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Indaptus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Indaptus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue1.3 K1.2 K

Pair Trading with Indaptus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Indaptus Stock

  0.53EWTX Edgewise TherapeuticsPairCorr
  0.31GOSS Gossamer BioPairCorr
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.